Vascular Gene Therapy

Radiographics

Volumn 18, Issue 6, 1998, Pages 1373-1394

  Thomas, John W ^a   Kuo, Michael D ^b   Chawla, Munish ^a   Waugh, Jacob M ^b   Yuksel, Eser ^b   Wright, Kenneth C ^a   Gerrity, Peg M ^c   Shenaq, Saleh M ^b   Whigham, Cliff J ^b   Fisher, Richard G ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NONE

Author keywords

Genes and genetics; Interventional procedures, experimental; Interventional procedures, technology

Indexed keywords

CORONARY ARTERY DISEASE; GENE THERAPY; GENE VECTOR; GRAFT OCCLUSION; HUMAN; INTERVENTIONAL RADIOLOGY; METHODOLOGY; PERIPHERAL VASCULAR DISEASE; REVIEW; THROMBOSIS; VASCULAR ENDOTHELIUM;

CORONARY DISEASE; ENDOTHELIUM, VASCULAR; GENE THERAPY; GENETIC VECTORS; GRAFT OCCLUSION, VASCULAR; HUMANS; PERIPHERAL VASCULAR DISEASES; RADIOLOGY, INTERVENTIONAL; THROMBOSIS;

EID: 0032199774     PISSN: 02715333     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiographics.18.6.9821188     Document Type: Article

References (109)

1. Blease RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270:475-480.
2. Culver KW, Anderson WF, Blaese RM. Lymphocyte gene therapy. Hum Gene Ther 1991; 2:107-109.
3. Isner JM, Walsh K, Symes J, et al. Clinical protocol: arterial gene transfer for therapeutic angiogenesis in patients with peripheral artery disease. Hum Gene Ther 1996; 7:959-988.
4. King RC, Stansfield WD. A dictionary of genetics. 5th ed. New York, NY: Oxford University Press, 1997.
5. Nabel EG, Pompili VJ, Plautz GE, Nabel GJ. Gene transfer and vascular disease. Cardiovascular Res 1994; 28:445-455.
6. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense, and antigene nucleic acids. Biochim Biophys Acta 1990; 1049:99-125.
7. Weintraub H. Antisense RNA and DNA. Scientific American 1990; 262:40-46.
8. Diasio RB, Zhang R. Pharmacology of therapeutic oligonucleotides. Antisense Nucleic Acid Drug Dev 1997; 7:239-243.
9. Cole-Strauss A, Yoon K, Xiang Y, et al. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide. Science 1996; 273:1386-1389.
10. Gimbrone MA Jr, Buchanan MR. Interactions of platelets and leukocytes with vascular endothelium: in vitro studies. Ann NY Acad Sci 1982; 401:171-183.
11. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. New Engl J Med 1990; 323:27-36.
12. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995; 267:518-522.
13. Reifers F, Kreuzer J. Current aspects of gene therapy: implications for vascular interventions. Mol Med 1995; 73:595-602.
14. Ledley FD, Anderson WF. Gene therapy for cardiovascular disease: an introduction. In: Mockrin SC, ed. Molecular genetics and gene therapy of cardiovascular diseases. New York, NY: Dekker, 1996; 467-485.
15. Nabel EG, Nabel GJ. Gene-transfer approaches to vascular disease. In: Mockrin SC, ed. Molecular genetics and gene therapy of cardiovascular diseases. New York, NY: Dekker, 1996; 487-511.
16. O'Malley BW, Ledley FD. Somatic gene therapy: methods for the present and future. Arch Otolaryngol Head Neck Surg 1993; 119:1100-1107.
17. Willard JE, Landau C, Glaman B, et al. Genetic modification of the vessel wall: comparison of surgical and catheter-based techniques for delivery of recombinant adenovirus. Circulation 1994; 5:2190-2197.
18. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997; 71:3293-3298.
19. Ross G, Erickson R, Knorr D, et al. Gene therapy in the United States: a five-year status report. Hum Gene Ther 1996; 7:1781-1790.
20. Felgner PL, Ringold GM. Cationic liposomes-mediated transfection. Nature 1989; 337:387-388.
21. Nabel EG, Plautz G, Nabel GJ. Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science 1990; 249: 1285-1288.
22. Roemer K, Fiedmann T. Concepts and strategies for human gene therapy. Eur J Biochem 1992; 208:211-225.
23. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10:4239-4242.
24. Baltimore D. RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 1970; 226:1209-1211.
25. Varmus H. Retroviruses. Science 1988; 240: 1427-1435.
26. Tolstoshev P. Gene therapy, concepts, current trials, and future directions. Ann Rev Pharmacol Toxicol 1993; 33:573-596.
27. Feldman LJ, Steg G, Zheng LP, et al. Low efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J Clin Invest 1995; 95:2662-2671.
28. Rome JJ, Shayani V, Newman KD, et al. Adenoviral vector-mediated gene transfer into sheep arteries using a double-balloon catheter. Hum Gene Ther 1994; 5:1249-1258.
29. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In vivo adenoviral vector-mediated gene transfer into balloon-injured rat carotid arteries. Circ Res 1993; 73:797-807.
30. Horwitz MS. Virology. New York, NY: Raven, 1990.
31. Cristiano RJ, Smith LC, Kay MA, Brinkley BR, Woo SL. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 1993; 90: 11548-11552.
32. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91:4407-4411.
33. Ilan Y, Prakash R, Davidson A, et al. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest 1997; 99:1098-1106.
34. Lieber A, He CY, Kay MA. Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo. Nature Biotech 1997; 15:1383-1387.
35. Schneider MD, French BA. The advent of adenovirus: gene therapy for cardiovascular disease. Circulation 1993; 88:1937-1942.
36. Zabner J, Peterson DM, Puga AP, et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nature Genet 1994; 6:75-83.
37. Prince GA, Porter DD, Jenson AB, Horswood RL, Chanock RM, Ginsberg HS. Pathogenesis of adenovirus type 5 pneumonia cotton rats (Sigmodon hispidus). J Virol 1993; 67:101-111.
38. Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo gene transfer into injured carotid arteries: optimization and evaluation of acute toxicity. Circulation 1995; 91:2407-2414.
39. Krisky D, Marconi P, Goins WF, Glorioso JC. Development of replication defective herpes simplex virus vectors. In: Robbins P, ed. Methods in molecular medicine, gene therapy protocols. Totowa, NJ: Humana, 1997.
40. Coffin RS, Howard MK, Cumming DV, et al. Gene delivery to the heart in vivo and to cardiac myocytes and vascular smooth muscle cells in vitro using herpes virus vectors. Gene Ther 1996; 3:560-566.
41. Morrow CD, Ansardi DC, Porter DC. Methods for the use of poliovirus vectors for gene delivery. In: Robbins P, ed. Methods in molecular medicine, gene therapy protocols. Totowa, NJ: Humana, 1997.
42. Khan SA, Sverdrup FM. Methods for the construction of human papillomavirus vectors. In: Robbins P, ed. Methods in molecular medicine, gene therapy protocols. Totowa, NJ: Humana, 1997.
43. Bartlett JS, Samulski RJ. Methods for the construction and propagation of recombinant adeno associated virus vectors. In: Robbins P, ed. Methods in molecular medicine, gene therapy protocols. Totowa, NJ: Humana, 1997.
44. Yeh P, Perricaudet M. Advances in adenoviral vectors: from genetic engineering to their biology. FASEBJ 1997; 11:615-623.
45. Bilbao G, Feng M, Rancourt C, Jackson WH Jr, Curiel DT. Adenoviral/retroviral vector chimeras: a novel strategy to achieve high-efficiency stable transduction in vivo. FASEB J 1997; 11:624-634.
46. Nabel EG, Yang Z, San H, Carr DP, Nabel GJ. Methods for liposome-mediated gene transfer to the arterial wall. In: Robbins P, ed. Methods in molecular medicine, gene therapy protocols. Totowa, NJ: Humana, 1997.
47. Dzau VJ, Mann MJ, Morishita R, Kaneda Y. Fusigenic viral liposome for gene therapy in cardiovascular diseases. Proc Natl Acad Sci USA 1996; 93:11421-11425.
48. Smith LC, Eisensmith RC, Woo SL. Gene therapy in heart disease. In: Longenecker JB, Kritchevsky D, Drezner MK, eds. Nutrition and biotechnology in heart disease and cancer. New York, NY: Plenum, 1995; 79-88.
49. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science 1989; 243: 375-378.
50. Cohen RJ, Paine PL. Biophysics of nucleocytoplasmic transport. In: Feldherr C, ed. Nuclear trafficking. New York, NY: Academic Press, 1992.
51. Gottschalk S, Sparrow JT, Hauer J, et al. A novel DNS-peptide complex for efficient gene transfer and expression in mammalian cells. Gene Ther 1996; 3:48-57.
52. Feero WG, Rosenblatt JD, Sirianni N, et al. Selection and use of ligands for receptor-mediated gene delivery to myogenic cells. Gene Ther 1997; 4:664-674.
53. Kircheis R, Kichler A, Wallner G, et al. Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther 1997; 4:409-418.
54. Felgner PL, Gadek TR, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad USA 1987; 84:7413-7417.
55. Carmeliet P, Collen D. Gene manipulation and transfer of the plasminogen and coagulation system in mice. Semin Thromb Hemost 1996; 22:525-542.
56. Zoldhelyi P, McNatt J, Xu XM, et al. Prevention of arterial thrombosis by adenovirus mediated transfer of cyclo-oxygenase gene. Circulation 1996; 93:10-17.
57. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nature Med 1996; 2:293-298.
58. Waugh JM, Kattash M, Li J, et al. Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model. Proc Natl Acad Sci USA (in press).
59. Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996; 93:301-309.
60. Steg PG, Tahlil O, Aubailly N, et al. Reduction of restenosis after angioplasty in an atheromatous rabbit model by suicide gene therapy. Circulation 1997; 96:408-411.
61. Guzman RJ, Hirschowitz EA, Brody SL, Crystal RG, Epstein SE, Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 1994; 91:10732-10736.
62. Simari RD, San H, Rekhter M, et al. Regulation of cellular proliferation and intimai formation following balloon injury in atherosclerotic rabbit arteries. J Clin Invest 1996; 98:225-235.
63. Ohno T, Gordon D, San H, et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265:781-784.
64. Harrell RL, Rajanayagam S, Doanes AM, et al. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation 1997; 96:621-627.
65. Yang ZY, Simari RD, Perkins ND, et al. Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc Natl Acad Sci USA 1996; 93:7905-7910.
66. Indolfi C, Awedimento EV, Rapacciuolo A, et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nature Med 1995; 1:541-545.
67. Kaneda Y, Morishita R, Dzau VJ. Prevention of restenosis by gene therapy. Ann NY Acad Sci 1997; 811:299-308.
68. Gibbons GH, Dzau VJ. Molecular therapies for vascular diseases. Science 1996; 272:689-693.
69. Zhu NL, Wu L, Liu PX, et al. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation 1997; 96:628-635.
70. Wu KK. Prostacyclin and nitric oxide-related gene transfer in preventing arterial thrombosis and restenosis. Agents Actions Suppl 1997; 48:107-123.
71. Asahara T Chen D, Tsurumi Y, et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 1996; 94:3291-3302.
72. Van Belle E, Tio FO, Chen D, et al. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimai thickening. J Am Coll Cardiol 1997; 29: 1371-1379.
73. Walters TK, Gorog DA, Wood RFM. Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process. J Vasc Res 1994; 31:173-177.
74. Trejo J, Connolly AJ, Coughlin SR. The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts: loss of responses in fibroblasts from receptor knockout mice. J Biol Chem 1996; 271:21536-21541.
75. Molino M, Bainton DF, Hoxie JA, Coughlin SR, Brass LF. Thrombin receptors on human platelets. J Biol Chem 1997; 272:6011-6017.
76. Jang Y, Guzman LA, Lincoff AM, et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92:3041-3050.
77. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. J Am Coll Cardiol 1991; 17(suppl B):96B-100B.
78. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77:863-868.
79. Dollery CM, McClelland A, Latchman DS, Henney AM, Humphries SE, McEwan JR. Adenoviral gene transfer of human TIMP-1 inhibits smooth muscle cell migration and neointima formation in injured rat carotid arteries. Presented at the 70th American Heart Association Scientific Sessions, Orlando, Florida, November 9-12, 1997.
80. Cheng L, Mantile G, Pauly R, et al. Adenovirus-mediated gene transfer of TIMP-2 inhibits neointimal hyperplasia after balloon injury. Presented at the 70th American Heart Association Scientific Sessions, Orlando, Florida, November 9-12, 1997.
81. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92:1137-1141.
82. Stephan D, Nabel EG. Gene and other biological therapies for vascular diseases. Fundam Clin Pharmacol 1997; 11:97-110.
83. Hedin U, Wahlberg E. Gene therapy and vascular disease: potential applications in vascular surgery. Eur J Vasc Endovasc Surg 1997; 13:101-111.
84. Feldman LJ, Tahlil O, Steg G. Perspectives of arterial gene therapy for the prevention of restenosis. Cardiovasc Res 1996; 32(2):194-207.
85. Nikol S, Huehns TY, Hofling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis 1996; 123:17-31.
86. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Comm 1989; 161:851-858.
87. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
88. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94:3281-3290.
89. Ibukiyama C. Angiogenesis: angiogenic therapy using fibroblast growth factors and vascular endothelial growth factors for ischemic vascular lesions. Jpn Heart J 1996; 37:285-300.
90. Muhlhauser J, Merrill MJ, Pili R, et al. VEGF165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res 1995; 77:1077-1086.
91. Isner JM, Trapnell BC, Rade JJ, Virmani R, Dicheck DA. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348:370-374.
92. Baumgartner I, Pieczek AM, Blair R, Manor O, Walsh K, Isner JM. Evidence of therapeutic angiogenesis in patients with critical limb ischemia after intramuscular phVEGF165 gene transfer. Presented at the 70th American Heart Association Scientific Sessions, Orlando, Florida, November 9-12, 1997.
93. Messina LM, Stanley JC. Endothelial cells: endothelium as a target organ for somatic gene therapy. In: Chang PL, ed. Somatic gene therapy. Boca Raton, Fl: CRC Press, 1995; 91-120.
94. Lynch CM, Clowes MM, Osborne WRA, Clowes AW, Miller AD. Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: a model for therapy. Proc Natl Acad Sci USA 1992; 89:1138-1142.
95. Nabel EG, Plautz G, Boyce FM, Stanley JC, Nabel GJ. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 1989; 244:1342-1344.
96. Wilson JM, Birinyi LK, Salomon RN, Libby P, Callow AD, Mulligan RC. Implantation of vascular grafts lined with genetically modified endothelial cells. Science 1989; 244:1344-1346.
97. Dichek DA, Neville RF, Zweibel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989; 80:1347-1353.
98. Dunn PF, Newman KD, Hones M, et al. Seeding of vascular grafts with genetically modified endothelial cells: secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation 1996; 93:1319-1320.
99. Lim CS, Chapman GD, Gammon RS, et al. Direct in vivo gene transfer into the coronary and peripheral vasculatures of the intact dog. Circulation 1991; 83:2007-2011.
100. Lemarchand P, Jones M, Yamada I, Crystal RG. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus. Cire Res 1993; 72:1132-1138.
101. Feldman LJ, Pastore CJ, Aubailly N, et al. Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Gene Ther 1997; 4:189-198.
102. Schulick AH, Dong G, Newman KD, Virmani R, Dichek DA. Endothelium-specific in vivo gene transfer. Circ Res 1995; 77:475-485.
103. Jejurikar SS, Welling TH, Zelenock JA, et al. Induction of angiogenesis by lidocaine and basic fibroblast growth factor: a model for in vivo retroviral-mediated gene therapy. J Surg Res 1997; 67:137-146.
104. Chapman GD, Lim CS, Gammon RS, et al. Gene transfer into coronary arteries of intact animals with a percutaneous balloon catheter. Circ Res 1992; 71:27-33.
105. Flugelman MY, Jaklitsch MT, Newman KD, Cassells W, Bratthauer GL, Dicheck DA. Low level in vivo gene transfer into the arterial wall through a perforated balloon catheter. Circulation 1992; 3:1110-1117.
106. Riessen R, Rahimizadeh H, Blessing E, Takeshita S, Barry JJ, Isner JM. Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. Hum Gen Ther 1993; 4:749-758.
107. Rome JJ, Shayani V, Flugelman MY, et al. Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall: modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. Arterioscler Thromb 1994; 14:148-161.
108. Tahlil O, Brami M, Feldman LJ, Branellec D, Steg PG. The Dispatch catheter as a delivery tool for arterial gene transfer. Cardiovasc Res 1997; 33:181-187.
109. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nature Med 1995; 1:1148-1154.